# DESCRIPTION

## BACKGROUND OF THE INVENTION

- motivate genetic mechanisms

## SUMMARY OF THE INVENTION

- define bifunctional compound
- describe degradation tag system
- outline methods of using dTAG and bifunctional compound
- describe in vivo methods
- highlight advantages of present invention

## DETAILED DESCRIPTION OF THE INVENTION

- define technical and scientific terms
- specify meaning of singular forms
- define "about"
- define transitional terms
- define alkyl
- define alkylene
- define alkenyl
- define alkoxyl and alkoxy
- define alkoxylene
- define cyclic group
- define carbocyclic
- define heterocyclyl
- provide examples of heterocyclyls
- define aryl
- define heteroaryl
- describe substituents
- define binding
- define FKBP12(F36V)-tagged protein
- describe bifunctional compound structure
- describe pharmaceutically acceptable salts
- describe isotopic derivatives
- describe stereoisomers
- describe chiral centers
- describe epimerization
- describe forms of bifunctional compounds

### Targeting Ligands

- define targeting ligand structure

### Linkers

- describe linker structure
- provide examples of alkylene-based linkers
- describe polyethylene glycol chain linkers
- provide examples of polyethylene glycol chain linkers
- describe linker variations

### Degrons

- define degron structure

### Methods of Synthesis

- describe method for making bifunctional compound
- provide synthetic schemes
- describe degradation tag system

### Proteins of Interest

- describe dTAG system for protein degradation
- list examples of proteins of interest

### Methods of Use

- describe in vitro methods
- genetically modify cells with FKBP12(F36V)
- contact modified cells with bifunctional compound
- detect change in cell property
- describe in vivo methods
- genetically modify cells with FKBP12(F36V) for in vivo use
- introduce modified cells into rodent
- administer bifunctional compound to rodent
- detect change in rodent property
- describe use of methods for protein target validation
- describe use of methods for tunable control of CRISPR-Cas9
- describe genomic insertion of dTAG
- describe CRISPR-Cas9 system for producing knock-in endogenous protein-dTAG fusion proteins
- describe insertion of exogenous dTAG sequence
- describe donor sequence and its introduction into cell
- describe CRISPR system and its elements
- introduce methods of use
- select guide sequence
- describe CRISPR-Cas system
- modify expression of polynucleotide
- administer polypeptides and donor sequence
- deliver nucleic acid sequences to cells
- describe viral vector systems
- describe non-viral delivery methods
- describe adenoviral based systems
- describe AAV vectors
- describe lentivirus vectors
- describe IDLV vectors
- describe packaging cells
- modify vector for specificity
- deliver vectors in vivo or ex vivo
- administer nucleic acids
- describe gene transfer methods

### Chimeric Antigen Receptor Protein (CAR)-dTAG Fusion Proteins

- introduce CAR-T cell therapy
- describe limitations of CAR-T cell therapy
- motivate need for safety strategies
- introduce CAR-dTAG fusion proteins
- describe structure of CAR-dTAG fusion proteins
- specify location of dTAG in CAR-dTAG fusion proteins
- provide examples of CAR-dTAG fusion proteins
- describe nucleic acid encoding CAR-dTAG fusion proteins
- outline method for preparing nucleic acid encoding CAR-dTAG fusion proteins
- describe engineering of immune effector cells expressing CAR-dTAG fusion proteins
- specify examples of immune effector cells
- outline therapeutic uses of CAR-dTAG fusion proteins
- describe administration of CAR-dTAG fusion proteins
- specify dosage amounts of CAR-dTAG fusion proteins
- outline pharmaceutical kits for CAR-dTAG fusion proteins

### Dosage Amounts

- define therapeutically effective amount
- specify factors affecting dosage amounts
- provide examples of dosage ranges

### Pharmaceutical Kits

- describe pharmaceutical kits for CAR-dTAG fusion proteins

## EXAMPLES

- describe synthesis of compounds

### Example 1: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (1)

- prepare compound A
- prepare compound B
- prepare compound C
- prepare compound 1

### Example 2: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(2-((7-(((S)-1-((2R,4S)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-7-oxoheptyl)amino)-2-oxoethoxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (2)

- prepare compound 2

### Example 3: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(((S)-16-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (S)-1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (3)

- prepare compound 3

### Example 4: Synthesis of (R)-3-(3,4-dimethoxyphenyl)-1-(2-(O)-16-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-17,17-dimethyl-2,14-dioxo-6,9,12-trioxa-3,15-diazaoctadecyl)oxy)phenyl)propyl (9-14(9-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate (4)

- prepare compound 4

### Example 5: Anti-Proliferation in NIH/3T3 Cells Expressing FKBP12F36V-KRASG12V by ATPlite™ Assay

- perform anti-proliferation assay

### Example 6: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

- perform immunoblotting

### Example 7: Immunoblotting of PATU-8902 LACZ-FKBP12F36V Clone

- perform immunoblotting

### Example 8: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V; KRAS−/− Clone

- perform immunoblotting to determine protein levels

### Example 9: Immunoblotting of PATU-8902 FKBP12F36V-KRASG12V KRAS−/− Clone

- treat cells with DMSO, Carflizomib or MLN4924
- perform immunoblotting to determine protein levels
- show degradation of FKBP12F36V-KRASG12V
- show rescue of degradation by proteasome-inhibitor or Nedd8 activating enzyme inhibitor
- indicate requirement of proteasome and activated E3 ligases for degradation
- summarize results

